Contrary to our results, the study of Zhang et al. showed that melanoma patients with PTPRT mutations harbored a significantly elevated ICI response rate and a prolonged survival outcome, and in the NSCLC cohort, the favorable response and immunotherapy survival were also observed in PTPRT-mutated patients [61]. Here, PTPRT is linked to melanoma.